111 related articles for article (PubMed ID: 15529587)
1. Remission induction in elderly acute myeloid leukemia by low-dose melphalan.
Gologan R; Ostroveanu D; Gioada L; Iacob V
Rom J Intern Med; 2003; 41(1):67-73. PubMed ID: 15529587
[No Abstract] [Full Text] [Related]
2. Low-dose melphalan in elderly patients with relapsed or refractory acute myeloid leukemia: A well-tolerated and effective treatment after hypomethylating-agent failure.
Stratmann J; van Kann E; Rummelt C; Koschade S; Röllig C; Lübbert M; Schaich M; Parmentier S; Sebastian M; Chromik J; Becker von Rose A; Ballo O; Steffen B; Serve H; Brandts C; Shaid S
Leuk Res; 2019 Oct; 85():106192. PubMed ID: 31445469
[TBL] [Abstract][Full Text] [Related]
3. Early discharge from hospital after consolidation chemotherapy in acute myeloid leukemia in remission: febrile neutropenic episodes and their outcome in a resource poor setting.
Naithani R; Kumar R; Mahapatra M; Agrawal N; Mishra P
Haematologica; 2008 Sep; 93(9):1416-8. PubMed ID: 18603560
[No Abstract] [Full Text] [Related]
4. [Encouraging results of stem cell transplantation following a melphalan-preceding intensified preparative regimen for refractory acute leukemia in children].
Inoue M; Yasui M; Sawada A; Koyama M; Kondo O; Miyamura T; Higuchi B; Kouroki M; Ishihara T; Kawa K
Rinsho Ketsueki; 2007 Nov; 48(11):1470-7. PubMed ID: 18080504
[TBL] [Abstract][Full Text] [Related]
5. Cholecystitis as the presenting manifestation of acute myeloid leukemia: report of a case.
Bloom SH; Coad JE; Greeno EW; Ashrani AA; Hammerschmidt DE
Am J Hematol; 2002 Jul; 70(3):254-6. PubMed ID: 12111774
[TBL] [Abstract][Full Text] [Related]
6. [Low dose melphalan therapy was effective in an elderly patient with MDS-AML].
Ontachi Y; Yamauchi H; Takami A; Asakura H; Nakao S
Nihon Ronen Igakkai Zasshi; 2001 May; 38(3):405-8. PubMed ID: 11431899
[TBL] [Abstract][Full Text] [Related]
7. A 28-year-old man with leukocytosis and anemia.
Narmala SK; Gandla KK; Verghese C; Bourgeois K; Boulmay BC
J La State Med Soc; 2010; 162(1):8-13. PubMed ID: 20336951
[No Abstract] [Full Text] [Related]
8. Long-term complete remission in IgD-myeloma.
Bemelmans RH; van Toorn DW; van Leeuwen L; Schaar CG
Eur J Haematol; 2006 Apr; 76(4):339-41. PubMed ID: 16519706
[TBL] [Abstract][Full Text] [Related]
9. [Clinical features and hematological factors relating to outcome of adult patients with acute myeloid leukemia who achieved complete remission].
Karasawa M; Tukamoto N; Nogiwa E; Yamauchi H; Iwata N; Omine M; Maekawa T; Murakami H; Nemoto K; Miyawaki S
Rinsho Ketsueki; 1988 Mar; 29(3):330-5. PubMed ID: 3165141
[No Abstract] [Full Text] [Related]
10. [Clinical effects of K-18 (IgG-melphalan) in hypoplastic leukemia: a case report].
Takahashi I; Ohmoto E; Nakada H; Inagaki N; Nonaka K; Takeuchi M; Osada K; Tsurumi N; Uchida K; Yorimitsu S
Gan To Kagaku Ryoho; 1988 Jan; 15(1):159-62. PubMed ID: 2447835
[TBL] [Abstract][Full Text] [Related]
11. Gelatinous transformation of bone marrow following chemotherapy for myeloma.
Mathew M; Mathews I; Manohar C; Rao S
Indian J Pathol Microbiol; 2001 Jan; 44(1):53-4. PubMed ID: 12561997
[TBL] [Abstract][Full Text] [Related]
12. Treatment of multiple myeloma in patients with Gaucher disease.
Machaczka M; Lerner R; Klimkowska M; Hägglund H
Am J Hematol; 2009 Oct; 84(10):694-6. PubMed ID: 19743447
[No Abstract] [Full Text] [Related]
13. G-CSF-induced remission in two cases of acute myeloid leukemia.
Benz R; Goede JS; Parlier V; Mühlematter D; Jotterand M; Fehr J
Leuk Res; 2008 Jul; 32(7):1148-52. PubMed ID: 18166225
[TBL] [Abstract][Full Text] [Related]
14. High-dose melphalan is an effective salvage therapy in acute myeloid leukaemia patients with refractory relapse and relapse after autologous stem cell transplantation.
Bug G; Atta J; Klein SA; Hertenstein B; Bergmann L; Boehrer S; Mousset S; Hoelzer D; Martin H
Ann Hematol; 2005 Oct; 84(11):748-54. PubMed ID: 16001243
[TBL] [Abstract][Full Text] [Related]
15. [Remission-influencing factors in acute myelogenic leukemia].
Love RR; Kaboth W
Med Klin; 1977 Apr; 72(15):631-6. PubMed ID: 323669
[No Abstract] [Full Text] [Related]
16. Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia.
Roboz GJ; Ritchie EK; Curcio T; Provenzano J; Carlin R; Samuel M; Wittenberg B; Mazumdar M; Christos PJ; Mathew S; Allen-Bard S; Feldman EJ
Cancer; 2008 Nov; 113(9):2504-11. PubMed ID: 18825661
[TBL] [Abstract][Full Text] [Related]
17. [Recent advances in the understanding and management of acute myeloid leukemia].
Lishner M; Buskila D; Ravid M
Harefuah; 1990 Dec; 119(11):375-8. PubMed ID: 2289717
[No Abstract] [Full Text] [Related]
18. High-dose melphalan and the development of hematopoietic stem-cell transplantation: 25 years later.
Lazarus HM; Phillips GL; Herzig RH; Hurd DD; Wolff SN; Herzig GP
J Clin Oncol; 2008 May; 26(14):2240-3. PubMed ID: 18467711
[No Abstract] [Full Text] [Related]
19. Low-dose melphalan induces favourable responses in elderly patients with high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia.
Denzlinger C; Bowen D; Benz D; Gelly K; Brugger W; Kanz L
Br J Haematol; 2000 Jan; 108(1):93-5. PubMed ID: 10651730
[TBL] [Abstract][Full Text] [Related]
20. Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia.
Giles F; Rizzieri D; Karp J; Vey N; Ravandi F; Faderl S; Khan KD; Verhoef G; Wijermans P; Advani A; Roboz G; Kantarjian H; Bilgrami SF; Ferrant A; Daenen SM; Karsten V; Cahill A; Albitar M; Mufti G; O'Brien S
J Clin Oncol; 2007 Jan; 25(1):25-31. PubMed ID: 17146105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
